Development of a miniature gamma-ray endoscopic probe for tumor localization in nuclear medicine

1993 ◽  
Vol 40 (2) ◽  
pp. 88-94 ◽  
Author(s):  
H. Watabe ◽  
T. Nakamura ◽  
H. Takahashi ◽  
M. Itoh ◽  
M. Matsumoto ◽  
...  
1997 ◽  
Vol 24 (11) ◽  
pp. 1701-1709 ◽  
Author(s):  
Mark F. Smith ◽  
Ronald J. Jaszczak
Keyword(s):  

Author(s):  
H.B. Barber ◽  
B.A. Apotovsky ◽  
F.L. Augustine ◽  
H.H. Barrett ◽  
E.L. Dereniak ◽  
...  

2021 ◽  
Vol 67 (6) ◽  
pp. 59-67
Author(s):  
M. S. Sheremeta ◽  
A. A. Trukhin ◽  
M. O. Korchagina

Nuclear medicine (NM) is a medical specialty that uses radionuclides (radioactive tracers) and ionising radiation for diagnostic and therapeutic (theranostic) purposes. Nuclear medicine arose and developed at the intersection of physics, chemistry and clinical medicine. The radiation emitted by radioisotopes can consist of gamma-, beta- and alpha emission, or it’s combination. Radioisotope of choice for medical purposes should have futher requirements: low radiotoxicity, suitable type of radiation, energy and half-life (several minutes to several hours and days), and also convenient detection of gamma ray radiation. The radionuclide is part of radiopharmaceutical (RP) and acts as its indicator. RP accumulates in morphological structures, becomes a carrier of coordinated information from patient to gamma camera or other equipment and reflects the dynamics of processes occurring in the examined organ. In 2021 NM celebrates its 80th anniversary. The trajectory of NM combines modern methods of radiotheranostics and applied genomic and post-genomic technologies.


1997 ◽  
Author(s):  
J.C. Lund ◽  
R.W. Olsen ◽  
R.B. James ◽  
E. Cross
Keyword(s):  

2020 ◽  
Vol 239 ◽  
pp. 23002
Author(s):  
Aurelian Luca ◽  
Mark A. Kellett

Since 2013, the radionuclide 223Ra is used in nuclear medicine to prepare radiopharmaceuticals for targeted radiotherapy. 223Ra is a member of the natural radioactive series of actinium and decays by alpha-particle emission, populating the excited levels of 219Rn. According to the 2011 nuclear decay data evaluation within the Decay Data Evaluation Project (DDEP), by V.P. Chechev, the half-life of 223Ra is (11.43 ± 0.03) days. The decay scheme is not considered as fully complete, because of the disagreement between the measured and calculated probabilities of some alpha-transitions and incomplete information on several gamma-ray transitions. New high quality measurements of 223Ra nuclear decay data were performed and numerous results were published since 2012 and, consequently, an updated nuclear decay data evaluation was undertaken, according to the DDEP procedures. The main results obtained, focusing on the recommended data improvements, are presented and discussed in this paper.


Sign in / Sign up

Export Citation Format

Share Document